Vimarsana
Biggest News Aggregation in the World

Page 9 - Combination Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Combination Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Combination Therapy Today - Breaking & Trending Today

Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC - Vimarsana News

Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC

Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.

COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA - Vimarsana News

COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

mCRC Treatment Sequencing Influenced By Combination Therapy - Vimarsana News

mCRC Treatment Sequencing Influenced By Combination Therapy

A recent FDA-approval is examined that provides new opportunities for effective combination strategies in mCRC treatment.

Source: ajmc.com
Evolving Treatment Strategies for Recurrent Low-Grade Serous Ovarian Cancer - Vimarsana News

Evolving Treatment Strategies for Recurrent Low-Grade Serous Ovarian Cancer

Expert oncologist Premal Thaker, MD, MS, reviews the current treatment landscape for recurrent low-grade serous ovarian cancer and considers the respective roles of various targeted agents in this setting.

The Role of Combination Therapy in mCRPC - Vimarsana News

The Role of Combination Therapy in mCRPC

Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.